GSK (GlaxoSmithKline) Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning. Welcome everybody to day two of the Jefferies Healthcare Conference this year. My name is Michael Leuchten. I am one of the European pharma analysts at Jefferies. Thank you for joining us early. It is my pleasure to host GSK today. We have got David Redfern, the head of BD at GSK, or President of BD, is also responsible for ViiV. I think we will do a little bit on ViiV, then we will do BD, and then a little bit broader on GSK and the recent changes. I hope I can make that work in 25 minutes. David, thank you for joining.
Maybe just starting with ViiV, I think you chaired it since 2011, and looking back, what would you say are the two or three decisions that most changed the direction of the business, and what lessons have been most relevant as we think about your transition of the portfolio to the long-acting injectables?
Great. Well, good morning everyone. Thanks, Michael, for having us. Thanks for Jefferies hosting everyone. Next year, you just need to fix the weather a little bit, I think. It is a great question on ViiV. I think probably two things, actually. If you go way back, when we developed dolutegravir, which is the oral integrase inhibitor that has really become the backbone standard of care, we knew we had a very potent molecule from the animal studies from phase II, 50 milligrams, very well tolerated. I think one of the key things we did in that phase III development program was not just study dolutegravir in virally suppressed patients, which was the normal, but we ran in parallel all types of people living with HIV, so people who had high viral load, naive patients, and so forth.
When we got approval for dolutegravir, we had a very, very broad label, and obviously it has gone on to be an enormous medicine. I think the second key thing was a decision we took over a decade ago to really focus our R&D money on long-acting. That was not a completely obvious decision because the daily orals in HIV had become very, very effective. If you talked to most doctors at that time, they were very satisfied. But there were two sort of key insights. One was patient insight. There were quite a significant number of people living with HIV that did not want to take daily oral pills every day. They felt a degree of stigma, anxiety, had not necessarily disclosed their status, and they really wanted to move to a long-acting injection.
And also, unfortunately, in the U.S., of the 1.2 million people living with HIV, only 60% or so are virally suppressed, despite the modern medicine. That is everything to do with access to the healthcare system. So there are still over 400,000 to 500,000 Americans that living in the rural South, lower income inner city, particularly African Americans, who are not virally suppressed. The only way to really treat that population effectively is with a long-acting injection. So we invested in that. Obviously, we launched the first medicine, Cabenuva, for treatment. That is every two months, and that is now grown into a very significant medicine and doing extremely well.
Great. Thank you. Then maybe one more on ViiV before I think most people are probably more interested in BD and GSK going forward. The long-acting strategy there is Cabenuva Q4M, so every four months.
Yeah. Then there is the every six monthly, which is a bit further out.
Can you just talk about timelines? Can you talk about, there was a slight hiccup with the Q4M PK/PD study. We are going to get CUATRO next year, which is the treatment every four months, Cabenuva. Just paint that picture, like what is the confidence into Cabenuva Q4M and into every six months with VH-184 and VH-499?
So 148. Yes. I mean, you have to separate the treatment market, which is about 90% of the overall HIV market, over GBP 22 billion from the PrEP prophylactic market, which is predominantly a U.S. market, about GBP 3 billion.
So in treatment, we have the first and only long-acting medicine on the market. As I said, Cabenuva doing very, very well now with very comprehensive dataset. We have a reformulated version of cabotegravir and rilpivirine in a pivotal study, the CUATRO study that you referred to. That has fully recruited, and we expect data on that probably the second half of next year. So that would potentially be on the market in 2028. Then we are developing a next generation integrase with a much broader resistance barrier, 184, with our own capsid inhibitor. That has the potential to be a sixth monthly regimen.
Both of those molecules are in phase II studies at the moment, and we are figuring out the formulation and the dose. We would hope to put those into pivotal studies probably somewhere around mid-2028. If we do that, we could potentially get that on the market early 2030s. I think that, as we move from every two months to every four months and then every six months, we will see a significant increase in the penetration of long-acting in the overall HIV treatment market. Certainly when we get to every six months, I think up to at least half the market could potentially switch. So that is very exciting. In PrEP, as you said, we have Apretude, which is every two months, doing pretty well in a growing market.
We have got data in-house on the four-month version of that, and we are in discussions with the regulator with that. I am not going to say more about that other than we are very, very confident in the formulation that we have got. The formulation actually of PrEP and the four-month version of cabotegravir is the same.
Got it. Okay. Amazing. Let us maybe pivot to BD. You have overseen corporate development across several different strategic eras at GSK. Can you talk about the philosophy of BD today and how it has changed, and what is distinctive about the current approach that you are pursuing?
We have been very active in BD this year and actually the last two or three years. Ever since, really, we demerged the Haleon business, the consumer business, reset the balance sheet, and became a pure play biopharma business. Like most large-cap pharmas, BD is an essential part of how we allocate capital. There is obviously fantastic science throughout the world to access. This year, we have done three pieces of M&A. We bought Nuvalent in the middle of the year, Boston-based precision oncology company. That was important to us because it was an important building step as we redevelop our oncology business, which is now going extremely well, and it gave us an entry into lung cancer for the first time. It has two precision molecules for ALK and ROS1 inhibitor. The ROS1 has been approved. The ALK we expect to be approved any day. So that is going well.
Behind that, in our own portfolio, we have a B7-H3 ADC from Hansoh that could also. We are in a pivotal study for small cell lung cancer at the moment, and potentially we are going to non-small cell lung cancer. There is no doubt under Luke Miels' now leadership, GSK is very much back in oncology, both blood cancers and solid tumors. We have a pretty extensive portfolio now. We are allocating a lot of capital to it, and you should certainly expect us to do more BD in oncology. We bought RAPT Therapeutics in the start of the year that has a food allergy antibody, very similar, same epitope as Xolair. Food allergy, as you can imagine, is growing very, very fast. Something like 18 million people in the United States have a significant food allergy.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
